
Photo from medicinespatentpool.org
Jun 22, 2023, 18:35
Generic manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of Novartis’ nilotinib – Medicines Patent Pool
Breaking | 4 generic manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of Novartis,’ nilotinib for the treatment of chronic myeloid leukaemia.
The four generic manufacturers companies include:
- Eugia Pharma Specialities Ltd (INDIA)
- Hetero (INDIA)
- Dr. Reddy’s Laboratories (INDIA)
- PT. Brightgene Biomedical Indonesia (INDONESIA)
Source: /Linkedin
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 10:07
Feb 21, 2025, 09:58
Feb 21, 2025, 09:54
Feb 21, 2025, 09:45
Feb 21, 2025, 09:35
Feb 21, 2025, 09:18
Feb 21, 2025, 09:07
Feb 21, 2025, 09:00
Feb 21, 2025, 08:19